Tesamorelin + Ipamorelin vs Tesamorelin

Tesamorelin + Ipamorelin wins for stacking synergy, higher peak GH/IGF-1 pulses, and a more robust VAT/liver fat recomposition effect per unit dose. It enables pronounced endogenous GH surges while minimizing cortisol/prolactin elevations, and is favored when maximal physiologic GH output is prioritized without resorting to supraphysiological exogenous HGH—especially for advanced recomp, tendon/sleep recovery, and pairing with GLP-1s.

Tesamorelin wins for simplicity, cleaner side-effect profile, and easier reconstitution/storage. As a single compound with precise phase 3 backing for VAT loss and minimal idiosyncratic effects, it is a concise, targeted solution for individuals wanting proven visceral fat/liver fat reduction protocols with less need for custom stacking or advanced handling techniques.

Pick Tesamorelin + Ipamorelin if:

• Synergistic, maximal GH and IGF-1 pulse is a priority (e.g., advanced recomp, tissue repair, microcycle recovery).
• Protocols combine VAT/liver fat loss with musculoskeletal or skin/connective tissue support.
• Pairing with GLP-1 analogs (semaglutide, tirzepatide) to preserve muscle during aggressive fat loss.
• Previous single-compound GHRH/GHRP approaches delivered moderate results and a more potent effect is desired.
• Endogenous GH secretion is to be maximized while avoiding exogenous HGH's water retention and "GH gut".

Pick Tesamorelin if:

• The research aims directly at VAT reduction, androgen "GH gut" correction, or NAFLD hepatic recomposition with minimal variables.
• Side-effect minimization and a simple, well-documented dosing schedule (1–2mg SC daily) are top priorities.
• Limited experience or infrastructure for peptide stacks—ease of sourcing, mixing, and storage matters.
• IGF-1 response and glucose metrics need clean attribution for monitoring/troubleshooting.
• The user is trialing their first GH-axis intervention and wants a single-compound protocol.